Glancy Prongay & Murray LLP Reminds Investors of the Deadline in the Class Action Lawsuit Against Nevro Corp.

LOS ANGELES–(BUSINESS WIRE)–$NVRO #CLASSACTION–National class action law firm Glancy
Prongay & Murray LLP
(“GPM”) reminds investors of the October
22, 2018 
deadline to file a lead plaintiff motion in the class
action filed on behalf of investors that purchased Nevro Corp. (“Nevro”
or the “Company”) (NYSE: NVRO)
securities between January 8, 2018 and July 12, 2018, inclusive
(the “Class Period”). Nevro investors have until October 22,
2018
to file a lead plaintiff motion.

If you are a shareholder who suffered a loss, click here to
participate.

In April 2017, Boston Scientific Corp. filed an action against Nevro,
asserting claims of patent infringement, theft of trade secrets and
tortious interference with contract by recruiting and hiring dozens of
former Boston Scientific Corp. employees.

Then, on July 10, 2018, various analysts reported on a tentative ruling
in Nevro’s ongoing patent litigation against Boston Scientific. The
tentative ruling invalidated at least five of the patents related to
Nevro’s purportedly “proprietary” HF10 therapy and Senza systems. On
this news, Nevro’s share price fell $11.43 per share, or 15.15%, to
close at $64.04 on July 10, 2018, thereby injuring investors.

The complaint filed in this class action alleges that the Company made
materially false and/or misleading statements during the class period
and/or failed to disclose that: (1) Nevro had engaged in a fraudulent
scheme by using protected confidential and proprietary trade secrets and
stolen documents from its competitors to develop and enhance the
Company’s Senza I and Senza II systems; (2) as a result, Nevro’s Senza I
and Senza II systems were not “novel” or “proprietary;” (3) these
practices caused Nevro to be vulnerable to increased litigation expenses
and adverse legal and regulatory action; (4) as a result, Nevro’s U.S.
sales growth was not sustainable; and (5) consequently, defendants’
statements about Nevro’s business, operations, and prospects, were
materially false and/or misleading and/or lacked a reasonable basis.

Follow us for updates on Twitter: twitter.com/GPM_LLP.

If you purchased shares Nevro during the Class Period you may move the
Court no later than October 22, 2018 to ask the Court to appoint
you as lead. To be a member of the Class you need not take any action at
this time; you may retain counsel of your choice or take no action and
remain an absent member of the Class. If you wish to learn more about
this action, or if you have any questions concerning this announcement
or your rights or interests with respect to these matters, please
contact Lesley Portnoy, Esquire, of GPM, 1925 Century Park East, Suite
2100, Los Angeles California 90067 at 310-201-9150, Toll-Free at
888-773-9224, by email to shareholders@glancylaw.com,
or visit our website at www.glancylaw.com.
If you inquire by email please include your mailing address, telephone
number and number of shares purchased.

This press release may be considered Attorney Advertising in some
jurisdictions under the applicable law and ethical rules.

Contacts

Glancy Prongay and Murray LLP, Los Angeles
Lesley Portnoy,
310-201-9150 or 888-773-9224
www.glancylaw.com
shareholders@glancylaw.com

leverton

I have been involved with publishing and marketing for the past 32 years. My passion is helping people share their voice. I am able to do this through two important venues: One, with Area-Info.net where people can share everything from opinions to events to news. It is your choice! What do you want to share? Two, through a new program called America's Real Deal I am involved with to help business owners get their voice heard.I schedule speaking engagements with community groups and business groups to share my passion about the importance of "sharing your voice".Contact me directly at lee@leeeverton.coom for scheduling information.